KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) EPS (Basic) (2018 - 2025)

Historic EPS (Basic) for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Q3 2025 value amounting to $0.01.

  • Amneal Pharmaceuticals' EPS (Basic) fell 7366.28% to $0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.02, marking a year-over-year increase of 10232.56%. This contributed to the annual value of -$0.38 for FY2024, which is 2066.95% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported EPS (Basic) of $0.01 as of Q3 2025, which was down 7366.28% from $0.07 recorded in Q2 2025.
  • Amneal Pharmaceuticals' EPS (Basic)'s 5-year high stood at $0.1 during Q2 2021, with a 5-year trough of -$0.8 in Q2 2022.
  • Over the past 5 years, Amneal Pharmaceuticals' median EPS (Basic) value was -$0.01 (recorded in 2022), while the average stood at -$0.08.
  • Within the past 5 years, the most significant YoY rise in Amneal Pharmaceuticals' EPS (Basic) was 40000.0% (2023), while the steepest drop was 176690.97% (2023).
  • Over the past 5 years, Amneal Pharmaceuticals' EPS (Basic) (Quarter) stood at -$0.04 in 2021, then grew by 25.0% to -$0.03 in 2022, then tumbled by 1766.91% to -$0.56 in 2023, then skyrocketed by 87.99% to -$0.07 in 2024, then skyrocketed by 114.87% to $0.01 in 2025.
  • Its EPS (Basic) stands at $0.01 for Q3 2025, versus $0.07 for Q2 2025 and $0.04 for Q1 2025.